Evotec SE
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammati… Read more
Evotec SE (EVOTF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.084x
Based on the latest financial reports, Evotec SE (EVOTF) has a cash flow conversion efficiency ratio of -0.084x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-67.56 Million) by net assets ($800.14 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Evotec SE - Cash Flow Conversion Efficiency Trend (2003–2024)
This chart illustrates how Evotec SE's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Evotec SE Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Evotec SE ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NPK International Inc.
NYSE:NPKI
|
0.054x |
|
The South Indian Bank Limited
NSE:SOUTHBANK
|
0.246x |
|
Willdan Group Inc
NASDAQ:WLDN
|
0.043x |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
|
0.030x |
|
Xior Student Housing BVBA
F:5XR
|
0.014x |
|
Jiangsu Lopal Tech Co Ltd
SHG:603906
|
-0.012x |
|
Innovex International, Inc
NYSE:INVX
|
0.049x |
|
Befar Group Co Ltd
SHG:601678
|
0.015x |
Annual Cash Flow Conversion Efficiency for Evotec SE (2003–2024)
The table below shows the annual cash flow conversion efficiency of Evotec SE from 2003 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $952.52 Million | $18.22 Million | 0.019x | -36.90% |
| 2023-12-31 | $1.12 Billion | $33.95 Million | 0.030x | -82.28% |
| 2022-12-31 | $1.19 Billion | $203.11 Million | 0.171x | +92.82% |
| 2021-12-31 | $1.38 Billion | $122.24 Million | 0.089x | +43.41% |
| 2020-12-31 | $722.85 Million | $44.72 Million | 0.062x | -30.09% |
| 2019-12-31 | $477.03 Million | $42.22 Million | 0.088x | -75.93% |
| 2018-12-31 | $424.88 Million | $156.24 Million | 0.368x | +1026.64% |
| 2017-12-31 | $331.75 Million | $10.83 Million | 0.033x | -89.63% |
| 2016-12-31 | $213.94 Million | $67.36 Million | 0.315x | +276.39% |
| 2015-12-31 | $187.09 Million | $15.65 Million | 0.084x | +448.94% |
| 2014-12-31 | $158.38 Million | $-3.80 Million | -0.024x | -157.25% |
| 2013-12-31 | $158.97 Million | $6.66 Million | 0.042x | -46.57% |
| 2012-12-31 | $152.55 Million | $11.96 Million | 0.078x | +13.75% |
| 2011-12-31 | $147.25 Million | $10.15 Million | 0.069x | +916.62% |
| 2010-12-31 | $132.64 Million | $899.00K | 0.007x | +103.46% |
| 2009-12-31 | $111.49 Million | $-21.85 Million | -0.196x | +28.84% |
| 2008-12-31 | $149.86 Million | $-41.28 Million | -0.275x | -48.33% |
| 2007-12-31 | $170.55 Million | $-31.67 Million | -0.186x | -176.14% |
| 2006-12-31 | $137.18 Million | $-9.22 Million | -0.067x | -367.85% |
| 2005-12-31 | $148.67 Million | $-2.14 Million | -0.014x | +95.28% |
| 2004-12-31 | $61.06 Million | $-18.60 Million | -0.305x | +22.88% |
| 2003-12-31 | $35.50 Million | $-14.02 Million | -0.395x | -- |